Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The new Erbitux data

On Sunday, Merck KGaA presented positive Phase II data for Erbitux cetuximab in colorectal cancer, providing a new benchmark for considering use of the antibody after ImClone's failed efforts to show efficacy in Phase II studies

Read the full 368 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE